Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Canada (NYSE:BHC) announced expanded access to its acne treatment CABTREO™ through the public drug plans of Quebec and Saskatchewan. This follows previous coverage announcements in Ontario, Nova Scotia, and federal programs including NIHB, CSC, and Veterans Affairs Canada.
CABTREO is a Canadian-made triple-combination topical prescription for treating acne vulgaris in patients 12 years and older. It is the first and only Health Canada-approved triple-combination treatment combining an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide) in a once-daily topical gel.
Bausch Health (NYSE:BHC) announced significant changes in its shareholding structure and board composition. Paulson Capital Inc. and its affiliates have acquired 34,721,118 common shares previously held by Carl C. Icahn's group, increasing their beneficial ownership to approximately 19.13% of the company's outstanding shares.
Following this transaction, the Director Appointment and Nomination Agreement with the Icahn Group has terminated, leading to the resignation of Brett M. Icahn and Steven D. Miller from the Board of Directors. John A. Paulson, Chairperson of the Bausch Health Board, expressed confidence in the company's value and its efforts to maximize shareholder value.
Bausch Health (NYSE:BHC) has announced the winners of its 2025 Salix Gastrointestinal Health Scholars Program. The company awarded $10,000 scholarships to 10 students living with GI diseases, marking the sixth consecutive year of the program. Selected from over 370 applicants, recipients were chosen across three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parent's Scholar Award.
The scholarship program aims to support students pursuing higher education while managing gastrointestinal conditions. Recipients were selected based on personal essays describing how their GI conditions have influenced their educational journey and the support received from healthcare providers.
Bausch Health (NYSE:BHC) reported strong Q2 2025 financial results with consolidated revenues of $2.53 billion, up 5% year-over-year. The company achieved GAAP Net Income of $148 million and Adjusted EBITDA of $842 million, marking its ninth consecutive quarter of growth.
Key segment performance includes Salix segment growth of 12% driven by Xifaxan®, Solta Medical segment growth of 25%, and Bausch + Lomb segment growth of 5%. The company announced plans to repay approximately $900 million in debt and entered an agreement to acquire DURECT Corporation to expand its hepatology portfolio.
Management reaffirmed its full-year 2025 guidance, projecting consolidated revenues of $10.0-10.25 billion and Adjusted EBITDA of $3.485-3.635 billion.
Bausch Health (NYSE:BHC) has announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX) in a deal valued at approximately $63 million upfront, with potential additional milestone payments of up to $350 million. The acquisition price represents a 217% premium to DURECT's closing price.
The key asset in this acquisition is larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for treating alcoholic hepatitis (AH). The drug has shown promising results in Phase 2 trials and addresses a significant unmet medical need, as AH accounts for 164,000 hospital admissions in the U.S. annually with no FDA-approved treatments currently available.
The transaction is expected to close in Q3 2025, subject to customary conditions including majority shareholder tender. The deal complements Bausch Health's existing hepatology portfolio, particularly their Phase 3 rifaximin SSD program.
Bausch Health (NYSE:BHC) has announced significant debt reduction initiatives totaling approximately $900 million. The company will redeem $602 million of its 9.25% Senior Notes due 2026 using cash on hand, with the redemption date set for August 28, 2025.
Additionally, Bausch's subsidiary plans to repay $300 million outstanding under its Receivables Facility, with termination scheduled for October 27, 2025. These strategic moves align with the company's objective to optimize its capital structure.
Bausch Health (NYSE:BHC) has expanded its Board of Directors from ten to twelve members with the appointment of two seasoned pharmaceutical industry executives, effective July 22, 2025. Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee.
Board Chairman John A. Paulson expressed confidence that their extensive industry experience and leadership capabilities will provide strategic guidance for the company's continued evolution and strengthen its commitment to stakeholders.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as two federal programs - the Non-Insured Health Benefits (NIHB) for Indigenous populations and the Correctional Service of Canada (CSC).
CABTREO is a first-of-its-kind triple-combination topical prescription treatment for acne vulgaris, approved by Health Canada for patients 12 years and older. The treatment combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel is currently available through most private insurance plans, with plans to expand access through other public drug plans across Canada.
Bausch Health (NYSE:BHC) has appointed Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025. Lee brings over two decades of experience in financial transformation, mergers and acquisitions, and operational execution.
Prior to joining Bausch Health, Lee served as Vice President and CFO of the Industrial and Energy Division and North America Division at BrandSafway, where he also held the position of Chief Accounting Officer. His previous experience includes leadership roles at Mohawk Industries as VP, Corporate Controller, and Chief Accounting Officer.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as federal programs NIHB and CSC. CABTREO is a first-of-its-kind triple-combination topical treatment for acne vulgaris in patients 12 years and older.
The prescription gel combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The treatment is administered once daily to affected skin areas and has already been available through most private drug insurance plans.